George Newman, MD
Internal Medicine · Knoxville, TNNPI 1083616957
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,170 of the $1,367 with a category attached, or 85.6%. It is spread thinly across 18 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $417 and has fallen 82.3% since, to $74 in 2025.
Across 69 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$217
- AstraZeneca$200
- GSK$149
- Nxstage Medical, Inc.$129
- Otsuka America Pharmaceutical, Inc.$96
- Akebia Therapeutics Inc$76
- plus $500 from 12 others
Across 227 payments — averaging $2999.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$269K
- Bayer$195K
- Merck$49K
- Boehringer Ingelheim$44K
- Vertex$33K
- Novartis$32K
- plus $59K from 10 others
What the payments were for
- Food & beverage$1,17086%
- Education$19714%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 13 | $217 |
| AstraZeneca(2 entities) | 10 | $200 |
| GSK | 8 | $149 |
| Nxstage Medical, Inc. | 1 | $129 |
| Otsuka America Pharmaceutical, Inc. | 1 | $96 |
| Akebia Therapeutics Inc | 5 | $76 |
| Vifor Pharma, Inc. | 4 | $66 |
| Novartis | 4 | $64 |
| Bayer | 4 | $59 |
| OPKO Pharmaceuticals, LLC | 4 | $52 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Travere Therapeutics, Inc. | 3 | $49 |
| Mallinckrodt Hospital Products Inc. | 3 | $45 |
| Aurinia Pharma U.S., Inc. | 2 | $39 |
| Medtronic | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,367 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 167 | $450,299 |
| AuryxiaFerric Citrate | 51 | $83,892 |
| Sevelamer Carbonate | 130 | $19,462 |
| Lanthanum Carbonate | 14 | $16,859 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $15,345 |
| KerendiaFinerenone | 22 | $15,241 |
| FarxigaDapagliflozin Propanediol | 15 | $8,530 |
| Midodrine Hcl | 39 | $2,083 |
| Calcium Acetate | 26 | $1,739 |
| Bumetanide | 43 | $1,323 |
| Labetalol Hcl | 18 | $1,269 |
| Hydralazine Hcl | 114 | $1,216 |
| Losartan Potassium | 136 | $1,081 |
| Calcitriol | 76 | $1,001 |
| Nifedipine ErNifedipine | 45 | $918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $76 | $83,89251 claims |
| AstraZenecaLokelma, Farxiga | $200 | $23,87634 claims |
| BayerKerendia | $59 | $15,24122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Knoxville
- Dennis DeruelleKnoxville$263K
- Lewis HagoodKnoxville$143K
- Antonio RamosKnoxville$20K
- Michael CollierKnoxville$17K
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
- Devin ShermanFranklin$191K
- Temidayo AbeNashville$113K
- Kenya KozawaSweetwater$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.